Asian Spectator

Men's Weekly

.

Singapore’s Biggest Beauty Sale Returns with $1 Deals, Rolex Prizes, and a BYD Electric Car Giveaway

SINGAPORE - Media OutReach Newswire - 17 July 2025 - Beauty Fiesta 2025 is set to dazzle beauty lovers once again with its most spectacular edition yet. Taking place at Singapore EXPO Hall 6A across ...

Asian Seed Congress: Asia-Pacific Region Leads Global Seed Trade, Innovation

HAIKOU, CHINA - Media OutReach Newswire - 6 December 2024 - From Dec. 2 to 6, the 29th Asian Seed Congress was held in Sanya, Hainan, bringing together over 1,500 participants from 52 count...

Landis+Gyr Announces FY 2021 Financial Results

CHAM, Switzerland, May 5, 2022 /PRNewswire-AsiaNet/-- Landis+Gyr (SIX: LAND) today announced unaudited financial results for financial year 2021 (April 1st, 2021 - March 31st, 2022). Key hig...

Chief Minister of Maharashtra, Eknath Shinde lines up MOUs in ...

DAVOS, Switzerland, Jan. 17, 2023 /PRNewswire-AsiaNet/ -- The Chief Minister of Maharashtra, India, Shri Eknath Shinde, has lined up 21 Memorandums of Understanding (MOUs) with leading forei...

Fondazione Prada Presents "Human Brains," A Multidisciplinary ...

MILAN, Oct. 14, 2020 /PRNewswire-AsiaNet/ -- "Human Brains" is a multidisciplinary project dedicated to brain studies taking place from November 2020 to November 2022. It is the result of a ...

NetDragon Announces Fiscal Year 2018 Financial Results; Record-High Revenue and Operating Profit

Segmental Financial HighlightsHONG KONG, Mar 26, 2019 - (ACN Newswire) - NetDragon Websoft Holdings Limited ('NetDragon' or the 'Company'; Hong Kong Stock Code: 777), a global leader in bui...

Microsoft announces new capabilities for a seamless, smart and...

REDMOND, Washington, Oct. 29, 2019 /PRNewswire-AsiaNet/-- New solutions deliver IoT innovations from cloud to edgeMicrosoft Corp. on Monday announced new capabilities that further simp...

Google Recognizes P3 as Accredited Android™ Automotive 3PL Vendor for AAOS Compliance / xTS

Highlights: Google has certified P3 as an accredited partner in its Third-Party Lab (3PL) Vendor program that ensures Android Automotive Operating System (AAOS) compliance. P3 was...

Kickstart Your Month with Kinohimitsu, iShopChangi Singapore’s Brand of the Month — Up to 78% Off Storewide

SINGAPORE - Media OutReach - 30 March 2023 - From 1 – 30 April, iShopChangi kickstarts the month with great April “fuels" from Kinohimitsu, its brand of the month. Enjoy fanta...

New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso Accepted by the National Medical Products Administration

New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso Accepted by the National Medical Products Administration

HONG KONG, May 26, 2020 - (ACN Newswire) - Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative R&D driven pharmaceutical conglomerate in the PRC, has announced that the new drug application of the anti PD-1 monoclonal antibody drug (generic name: Penpulimab; R&D code: AK105) jointly developed and commercialized with Akeso, Inc. (HKEX: 9926), a biopharmaceutical company committed to R&D, production and commercialization of affordable innovative antibody drugs for patients worldwide, has been accepted by the National Medical Products Administration of the PRC, for the treatment of patients with relapsed or refractory Classical Hodgkin's Lymphoma.

Classical Hodgkin Lymphoma (cHL) is a B-cell lymphoma, and is also one of the most common malignancies among young people. It has a single modal age distribution in China with a peak at around 40 years of age . cHL is one of the few tumors that can be cured, and the most common therapy is chemotherapy plus radiotherapy, with the 5-year survival rate of patients as high as over 80%. Although the first-line chemotherapy has a high clinical cure rate, a considerable portion of patients are insensitive to chemotherapy and approximately 5% to 10% of patients do not respond to the initial treatment .

Professor Zhu Jun, Co-principal investigator of the lead unit Beijing Cancer Hospital is full of expectations for such a differentiated anti PD-1 monoclonal product and said, through bioengineering technology, Penpulimab completely eliminate the binding activity of Fc receptors and avoid the antibody-dependent cell-mediated cytotoxicity (ADCC) effect. At the same time, compared with other drugs available in the market working on the same target, it has a slower rate of antigen binding and dissociation, which makes the biological effect stronger and improves its anti-tumor activity.

Co-lead researcher Professor Song Yuqin, Director of Lymphoma Department at Peking University Cancer Hospital said, in clinical trial, Penpulimab was observed with gratifying therapeutic data and good safety. As a clinician, Professor Song hoped that Penpulimab can be launched to the market soon, which will benefit more patients and their families.

About Sino Biopharmaceutical Limited (HKEX: 1177)Sino Biopharmaceutical Limited is a leading, innovative R&D driven pharmaceutical conglomerate in the PRC. Its business encompasses a fully-integrated chain which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemical medicines for treating tumors, liver diseases, respiratory system diseases, anti-infectious diseases and orthopedic diseases.

Sino Biopharm is a constituent stock of the following indices: MSCI Global Standard Indices - MSCI China Index, Hang Seng Index, Hang Seng Index - Commerce & Industry, Hang Seng Composite Index, Hang Seng Composite Industry Index - Consumer Goods, Hang Seng Composite LargeCap Index, Hang Seng Composite LargeCap & MidCap Index, Hang Seng China (Hong Kong-listed) 100 Index and Hang Seng Stock Connect Hong Kong Index. Sino Biopharm was ranked as one of "Asia's Fab 50 Companies" by Forbes Asia for three consecutive years in 2016, 2017 and 2018. http://www.sinobiopharm.com/.

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Tarif impor AS ke Indonesia: seberapa berdampak terhadap pertumbuhan ekonomi nasional?

Presiden Amerika Serikat, Donald Trump, mengumumkan penyesuaian kebijakan tarif impor baru bagi Indonesia menjadi 19%. Hal ini diklaim buah hasil negosiasi perdagangan antara kedua negara yang memberi...

Cara membuat prompt AI yang bagus biar produktif: tip dari ahli

FOTOSPLASH/Shutterstock“Apakah kamu mampu memanfaatkan AI dalam pekerjaan?”Kecerdasan buatan alias artificial intelligence (AI) sudah jadi bagian dari keseharian kita. Mulai dari ChatGPT, ...

Cara membahas masalah tanpa menimbulkan pertengkaran: Tip dari ahli

Pormezz / ShutterstockKita sebagai manusia memiliki perbedaan satu sama lain yang memengaruhi pendapat kita. Maka dari itu, ada kalanya kita tidak setuju dengan pendapat orang lain.Berbeda pendapat ka...